- Home
- MRCC vs IPSC Comparison
MRCC vs IPSC Comparison
Compare MRCC & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- IPSC
- Stock Information
- Founded
- MRCC 2011
- IPSC 2019
- Country
- MRCC United States
- IPSC United States
- Employees
- MRCC N/A
- IPSC N/A
- Industry
- MRCC Investment Managers
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- MRCC Finance
- IPSC Health Care
- Exchange
- MRCC Nasdaq
- IPSC Nasdaq
- Market Cap
- MRCC 176.4M
- IPSC 49.6M
- IPO Year
- MRCC 2012
- IPSC 2021
- Fundamental
- Price
- MRCC $6.46
- IPSC $0.56
- Analyst Decision
- MRCC Hold
- IPSC Strong Buy
- Analyst Count
- MRCC 1
- IPSC 5
- Target Price
- MRCC $8.00
- IPSC $3.33
- AVG Volume (30 Days)
- MRCC 91.8K
- IPSC 1.1M
- Earning Date
- MRCC 08-06-2025
- IPSC 08-07-2025
- Dividend Yield
- MRCC 15.48%
- IPSC N/A
- EPS Growth
- MRCC 3301.50
- IPSC N/A
- EPS
- MRCC 0.32
- IPSC N/A
- Revenue
- MRCC $56,983,000.00
- IPSC $114,898,000.00
- Revenue This Year
- MRCC N/A
- IPSC $1,064.82
- Revenue Next Year
- MRCC N/A
- IPSC N/A
- P/E Ratio
- MRCC $19.88
- IPSC N/A
- Revenue Growth
- MRCC N/A
- IPSC 8286.72
- 52 Week Low
- MRCC $6.11
- IPSC $0.34
- 52 Week High
- MRCC $8.85
- IPSC $3.29
- Technical
- Relative Strength Index (RSI)
- MRCC 50.70
- IPSC 47.48
- Support Level
- MRCC $6.19
- IPSC $0.52
- Resistance Level
- MRCC $6.65
- IPSC $0.57
- Average True Range (ATR)
- MRCC 0.15
- IPSC 0.03
- MACD
- MRCC 0.02
- IPSC -0.01
- Stochastic Oscillator
- MRCC 50.88
- IPSC 40.00
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.